Biotechnology Value Trading Fund OS LP
Director at Kymera Therapeutics; Insider at Cullinan Therapeutics; Director at Olema Oncology.
- Rank
- 731st of 809
- Companies held
- 6
- Largest holding
- KYMR, 89.7% of total
- Latest SEC filing
- Jun 24, 2026
What the $64.4M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Kymera Therapeutics KYMR Common Stock, $0.0001 par value | Directly | 353,412 | $119.39 | $42.2M | 65.5% | Form 4, Jun 24, 2026 |
| Kymera Therapeutics KYMR Common Stock, $0.0001 par value | Indirectly (see filing footnote) | 130,645 | $119.39 | $15.6M | 24.2% | Form 4, Jun 24, 2026 |
| Cullinan Therapeutics CGEM Common Stock | Directly | 319,415 | $9.07 | $2.9M | 4.5% | Form 4, May 13, 2022 |
| Olema Oncology OLMA Common stock, $0.0001 par value | Directly Reported jointly by 2 insiders; split evenly | 262,076 | $7.15 | $1.9M | 2.9% | Form 4, Sep 12, 2023 |
| Olema Oncology OLMA Common stock, $0.0001 par value | Indirectly (see filing footnote) | 99,556 | $7.15 | $712K | 1.1% | Form 4, Sep 14, 2023 |
| Verastem VSTM Common Stock | Directly | 82,863 split-adjusted | $6.86 | $568K | 0.9% | Form 3, Jan 25, 2022 |
| Immunic IMUX Common Stock, $0.0001 par value | Directly | 42,763 split-adjusted | $7.39 | $316K | 0.5% | Form 3, Feb 17, 2026 |
| Eledon Pharmaceuticals ELDN Common Stock, $0.001 par value | Directly | 145,029 | $1.90 | $276K | 0.4% | Form 4, May 5, 2023 |
Share counts are the amounts Biotechnology Value Trading Fund OS LP reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 728 | Pioneer Acquisition 1 Sponsor Holdco LLC 10% owner, Pioneer Acquisition I | $65.9M |
| 729 | Rosalind Advisors, Inc. Director, Delcath Systems | $65.2M |
| 730 | venBio Global Strategic Fund IV, L.P. 10% owner, Attovia Therapeutics | $65.1M |
| 731 | Biotechnology Value Trading Fund OS LP Director, Kymera Therapeutics | $64.4M |
| 732 | Transcontinental Realty Investors INC 10% owner, Income Opportunity Realty Investors | $64.0M |
| 733 | Paddington Partners 88 LLC CEO, Quantum Leap Acquisition | $63.6M |
| 734 | Union Investments & Development Ltd. 10% owner, Xtend AI Robotics | $63.5M |
Other Kymera Therapeutics insiders
All KYMR insiders- Nello Mainolfi$79.6MChief Executive Officer. #1805 overall
- Bruce N. Jacobs$29.2MChief Financial Officer. #3859 overall
- Jared Gollob$14.0MChief Medical Officer. #6806 overall
- Ellen Chiniara$9.6MChief Legal Officer. #9086 overall
- Brian Adams$6.0MChief Legal Officer. #7698 overall
- Noah Goodman$5.6MChief Business Officer. #13327 overall
Questions
How much stock does Biotechnology Value Trading Fund OS LP own?
Biotechnology Value Trading Fund OS LP holds $64,434,336 in listed stock based on SEC filings and current prices, mostly Kymera Therapeutics (KYMR). That ranks 731st on the Stock Rich List.
Is this Biotechnology Value Trading Fund OS LP's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
Files jointly with SEC filer 1233840.